Related Experiment Video
Updated: May 15, 2026

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers
Published on: October 17, 2013
Current perspectives on the US FDA regulatory framework for intelligent drug-delivery systems
Kim E Sapsford1, Kristina Lauritsen, Katherine M Tyner
1Office of Science & Engineering Laboratories, Center for Devices & Radiological Health, USA.
Abstract:
The US FDA is the US agency responsible for regulating intelligent drug-delivery systems (IDDS). IDDS can be classified as a device, drug, biologic or combination product. In this perspective, the current regulatory framework for IDDS and future perspectives on how the field is expected to evolve from a regulatory standpoint is discussed.
Related Concept Videos
Modified-Release Drug Delivery Systems: Overview
Modified-Release Drug Delivery Systems: Stimuli-Activated
Oral Drug Delivery Systems: Introduction
Modified-Release Drug Delivery Systems: Influencing Factors
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Modified-Release Drug Delivery Systems: Classification
